Nicox signs exclusive distribution agreement with Nitto

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nicox signs exclusive distribution agreement with Nitto Medic for AdenoPlus(r) in Japan

SOPHIA ANTIPOLIS, France, Aug. 29, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has entered into an exclusive agreement with Nitto Medic, a leading Japanese ophthalmic company, for the distribution in Japan of AdenoPlus ® , a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. Nicox has worldwide rights outside North America for AdenoPlus ® as per an agreement with Rapid Pathogen Screening, Inc. (RPS ® ).

Michele Garufi, Chairman and Chief Executive Officer of Nicox , said: " We are delighted to sign this agreement with Nitto Medic, a leader in the Japanese ophthalmic sector, as our exclusive distributor for AdenoPlus ® in this market, which is the second largest of the world 1 . We believe that the high accuracy of AdenoPlus ® and its easy-to-use characteristics, together with the relationships of Nitto Medic amongst Japanese ophthalmologists, will contribute to the success of this innovative diagnostic tool. "

Ryu Nakai, President and Chief Executive Officer of Nitto Medic , commented: " We are very excited about this agreement with Nicox. We are confident that AdenoPlus ® will greatly contribute to the healthcare and welfare of people in Japan. We do hope that this first agreement with Nicox will be the beginning of a long-lasting collaboration as well as on future product opportunities. "

Under the terms of the agreement, Nitto Medic will become the exclusive distributor of AdenoPlus ® in Japan. Nitto Medic will pay a €500,000 upfront payment to Nicox and will purchase the AdenoPlus ® devices from Nicox. Nitto Medic will be responsible for obtaining the relevant regulatory approval in Japan before launch. AdenoPlus ® is expected to be launched in Japan within the next 18 months, pending regulatory approval.

About AdenoPlus ®

AdenoPlus ® is an in vitro diagnostic medical device that aids in the identification of adenovirus to assist in the differential diagnosis of acute conjunctivitis. Correct diagnosis of viral conjunctivitis can help to reduce the inappropriate use of antibiotics. Nicox in-licensed AdenoPlus ® from RPS ® in June 2012 and has full exclusive rights to commercialize AdenoPlus ® worldwide, except in the United States and Canada. Nicox launched AdenoPlus ® in the five main European markets (France, Germany, Italy, Spain and the UK) through its own sales force in the first half of 2014, and has established partnerships with third parties in other territories, including Switzerland, Turkey, Benelux, South Africa and Poland.

About Nitto Medic

Nitto Medic is a leading Japanese specialist in ophthalmology drugs, manufactured in its Toyama-based FDA-approved plant. Nitto Medic is based in Toyama, Japan, and was founded in 1994. Its main products include ophthalmic solutions, ophthalmic ointments, nasal sprays, oral drugs, in-vitro diagnostics and eyewash solutions. For more information, please visit www.nittomedic.co.jp .

...................................

Reference

  1. Ophthalmic Drugs: World Market Prospects 2013-2023, Vision Gain 2013.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com .


..................................

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2013 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website ( www.nicox.com ) and on the AMF's website ( www.amf-france.org ).

...................................

Contacts  
Nicox Gavin Spencer  |   Executive Vice President Corporate Development
  +33 (0)4 97 24 53 00 | communications@nicox.com
   
Media Relations  
   
United States    Justin W. Jackson | Burns McClellan, Inc.
  +1 212 213 0006 | jjackson@burnsmc.com
   
United Kingdom     Jonathan Birt
  +44 7860 361 746 | jonathan.birt@ymail.com
   
France Caroline Courme | Communication Manager
  +33 (0)4 97 24 53 43 | courme@nicox.com

Press release http://hugin.info/143509/R/1851924/647043.pdf

HUG#1851924

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Daniel Pink on Leadership and Workplace Evolution Insights

Updated Category News Views 424

Exploring Leadership in a Changing Workplace The recent episode of Info-Tech Research Group's podcast, Digital Disruption, highlights a thought-provoking discussion with bestselling author Daniel Pink, focusing on how leaders can adapt in a time he describes as 'the great sort'. This term encapsulates the ongoing transformation in our approach to work, leadership, and the...

Continue Reading
MORSE Corp's Community Cleanup Initiative: Making an Impact

Updated Category News Views 240

MORSE Corp's Commitment to Community Service MORSE Corp recently dedicated an entire day to community service by hosting a cleanup initiative at local beaches and parks. On a beautiful Wednesday, the organization mobilized its team to gather at a coastal spot to improve the environment and promote community spirit. This initiative is part of their annual effort to...

Continue Reading
FDA's New Proposal to Enhance Nutrition Awareness on Food Labels

Updated Category News Views 125

Revolutionizing Nutrition Transparency for Consumers Today, the U.S. Food and Drug Administration (FDA) is taking significant steps towards improving consumer awareness about the nutritional value of packaged foods. A new proposal dictates that most packaged foods will require a prominent front-of-package (FOP) nutrition label. This initiative is part of a broader...

Continue Reading
CW Bancorp Declares Quarterly Dividend for Shareholders

Updated Category News Views 150

CW Bancorp Announces Dividend Declaration CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, has approved a quarterly cash dividend. The news comes as the company continues to prioritize shareholder value while supporting its growth journey. Details of the Cash Dividend The Board of Directors of CW Bancorp declared a cash dividend of $0.23 per common...

Continue Reading
Universal Electronics Unveils QuickSet homeSense at CES Event

Updated Category News Views 348

Universal Electronics Introduces QuickSet homeSense Technology Universal Electronics Inc. (NASDAQ: UEIC) has made headlines by launching its innovative QuickSet homeSense technology. This introduction took place at the prestigious International Consumer Electronics Show (CES) where the spotlight is often on groundbreaking tech. UEI, a leader in wireless control solutions,...

Continue Reading